ZA200109901B - Method for down-regulating GDF-8 activity. - Google Patents

Method for down-regulating GDF-8 activity.

Info

Publication number
ZA200109901B
ZA200109901B ZA200109901A ZA200109901A ZA200109901B ZA 200109901 B ZA200109901 B ZA 200109901B ZA 200109901 A ZA200109901 A ZA 200109901A ZA 200109901 A ZA200109901 A ZA 200109901A ZA 200109901 B ZA200109901 B ZA 200109901B
Authority
ZA
South Africa
Prior art keywords
activity
gdf
regulating
regulating gdf
Prior art date
Application number
ZA200109901A
Other languages
English (en)
Inventor
Torben Halkier
Steen Klysner
Soren Mouritsen
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of ZA200109901B publication Critical patent/ZA200109901B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Debugging And Monitoring (AREA)
ZA200109901A 1999-07-20 2001-11-30 Method for down-regulating GDF-8 activity. ZA200109901B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26

Publications (1)

Publication Number Publication Date
ZA200109901B true ZA200109901B (en) 2003-05-28

Family

ID=26065065

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109901A ZA200109901B (en) 1999-07-20 2001-11-30 Method for down-regulating GDF-8 activity.

Country Status (21)

Country Link
US (2) US7070784B1 (fr)
EP (1) EP1200119A2 (fr)
JP (1) JP2003506325A (fr)
KR (1) KR100750695B1 (fr)
CN (1) CN1384757A (fr)
AU (1) AU778470B2 (fr)
CA (1) CA2379852A1 (fr)
EA (1) EA005248B1 (fr)
EE (1) EE200200025A (fr)
HK (1) HK1048937A1 (fr)
HR (1) HRP20010900A2 (fr)
HU (1) HUP0201861A3 (fr)
IL (1) IL146845A0 (fr)
MX (1) MXPA01013232A (fr)
NO (1) NO20016252L (fr)
NZ (1) NZ517058A (fr)
PL (1) PL353855A1 (fr)
SK (1) SK722002A3 (fr)
TR (2) TR200400621T2 (fr)
WO (1) WO2001005820A2 (fr)
ZA (1) ZA200109901B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
CA2331410C (fr) * 1998-05-06 2009-07-14 Metamorphix, Inc. Methodes de traitement du diabete par inhibition du gdf-8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003260748A1 (en) * 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
MXPA05006521A (es) * 2002-12-20 2005-08-26 Amgen Inc Agentes de enlace que inhiben miostatina.
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
ATE552272T1 (de) 2004-09-30 2012-04-15 Orico Ltd Myostatin-isoform
JP5415071B2 (ja) 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
EP2054434B1 (fr) 2006-08-03 2017-03-15 Myostin Therapeutics Pty Ltd Antagonistes vis-à-vis de la myostatine
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US20140223592A1 (en) * 2011-07-06 2014-08-07 Pig Myostatin Gene Locus And Uses Thereof Pig myostatin gene locus and uses thereof
ES2663946T3 (es) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A
EP2861617A1 (fr) 2012-06-15 2015-04-22 Pfizer Inc. Anticorps antagonistes améliorés dirigés contre gdf-8 et leurs utilisations
SI2880053T1 (sl) 2012-08-01 2020-08-31 Ikaika Therapeutics, Llc Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4
IL301607A (en) 2013-05-06 2023-05-01 Scholar Rock Inc Preparations and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (fr) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Trousse de diagnostic et procédé pour l'identification de la manipulation de la masse musculaire chez un animal domestique
EP3283519A1 (fr) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
CN113347990A (zh) 2018-12-21 2021-09-03 西北大学 膜联蛋白在预防和治疗肌膜损伤中的用途
WO2020139977A1 (fr) 2018-12-26 2020-07-02 Northwestern University Utilisation de stéroïdes de glucocorticoïdes dans la prévention et le traitement de l'atrophie musculaire, du vieillissement et du trouble métabolique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
WO1995007707A1 (fr) 1993-09-14 1995-03-23 Cytel Corporation Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
SI0975668T1 (sl) 1997-04-15 2007-02-28 Pharmexa As Modificirana molekula TNFalfa, DNA, ki kodira tako modificirano molekulo TNFalfa in cepivo, ki vsebuje tako modificirano molekulo TNFalfa in DNA
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
JP2003528024A (ja) * 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
HRP20010900A2 (en) 2003-08-31
EE200200025A (et) 2003-04-15
AU5967500A (en) 2001-02-05
AU778470B2 (en) 2004-12-09
EA200200182A1 (ru) 2002-06-27
MXPA01013232A (es) 2005-05-24
WO2001005820A2 (fr) 2001-01-25
KR20020026544A (ko) 2002-04-10
US7056512B1 (en) 2006-06-06
NZ517058A (en) 2004-04-30
TR200200133T2 (tr) 2002-05-21
SK722002A3 (en) 2003-02-04
HUP0201861A3 (en) 2004-07-28
WO2001005820A3 (fr) 2001-07-19
EA005248B1 (ru) 2004-12-30
EP1200119A2 (fr) 2002-05-02
KR100750695B1 (ko) 2007-08-22
CN1384757A (zh) 2002-12-11
NO20016252D0 (no) 2001-12-19
TR200400621T2 (tr) 2004-08-23
NO20016252L (no) 2002-03-15
JP2003506325A (ja) 2003-02-18
US7070784B1 (en) 2006-07-04
PL353855A1 (en) 2003-12-01
HK1048937A1 (zh) 2003-04-25
IL146845A0 (en) 2002-07-25
HUP0201861A2 (en) 2002-09-28
CA2379852A1 (fr) 2001-01-25

Similar Documents

Publication Publication Date Title
ZA200109901B (en) Method for down-regulating GDF-8 activity.
EP1143806A3 (fr) Procede permettant d'augmenter l'activite chez les animaux domestiques
ZA200107525B (en) Improved attachment method for piezoelectric elements.
ZA200202843B (en) Method for improving growth.
EP1198306A4 (fr) Technique d'encapsulation permettant de maintenir une activite de decontamination biologique
MXPA01010625A (es) Metodo para regulacion por disminucion de la actividad de interleucina 5.
HUP0103611A2 (en) Process for selective lactonization
GB0007871D0 (en) Method
GB2355455B (en) Method
IL140058A0 (en) Methods for inhibiting tef-3 activity
GB9911939D0 (en) Method
HU9902898D0 (en) Method for influancing thermosensibility
GC0000055A (en) Method for making dimethylnaphthalenes.
HU9904385D0 (en) Method for akkumulator change
HU9901405D0 (en) Method for economical gold-washing
GB9914913D0 (en) Method
GB0200956D0 (en) Method
GB0007007D0 (en) Method
GB9901132D0 (en) Method
GB9901583D0 (en) Method
GB9903934D0 (en) Method
GB9905234D0 (en) Method
GB9905669D0 (en) Method
GB9909988D0 (en) Method
GB9906852D0 (en) Method